Skip to content

Trial · Interventional

CompletedPhase 2Results postedRegistry data

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

NCTNCT03201419 (opens ClinicalTrials.gov in a new tab)Other id000233Other id2016-003851-31Other id2016

Overview

Status
Completed
Phase
Phase 2
Enrollment
302 participants (actual)
Sponsor
Ferring Pharmaceuticals · Industry
Design
Randomized · Double masking
Countries
7 countries

United States, Belgium, Canada, Czechia, Germany, Hungary, Poland

Start
27 Jul 2017
Primary completion
31 Oct 2019
Completion
31 Oct 2019
First posted
28 Jun 2017
Last update posted
2 Mar 2022
Conditions
Nocturia

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2017201820192020
  1. Ph 2

    A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

    NCT03201419

    27 Jul 2017 to 31 Oct 2019

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults

Interventions

  • FE 201836Drug
  • DesmopressinDrug
  • Placebo oral solutionDrug
  • Placebo ODTDrug

Arms9

  • Experimental

    FE 201836 500 μg (Randomized Treatment Period)

    FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily

  • Experimental

    FE 201836 350 μg (Randomized Treatment Period)

    FE 201836 350 μg oral solution and placebo ODT, administered once daily

  • Experimental

    FE 201836 250 μg (Randomized Treatment Period)

    FE 201836 250 μg oral solution and placebo ODT, administered once daily

  • Experimental

    FE 201836 150 μg (Randomized Treatment Period)

    FE 201836 150 μg oral solution and placebo ODT, administered once daily

  • Experimental

    FE 201836 100 μg (Randomized Treatment Period)

    FE 201836 100 μg oral solution and placebo ODT, administered once daily

  • Experimental

    FE 201836 50 μg (Randomized Treatment Period)

    FE 201836 50 μg oral solution and placebo ODT, administered once daily

  • Experimental

    Placebo (Randomized Treatment Period)

    Placebo oral solution and placebo ODT, administered once daily

  • Experimental

    Desmopressin 25 μg (Randomized Treatment Period)

    Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)

  • Experimental

    Desmopressin 50 μg (Randomized Treatment Period)

    Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment

    Time frame · Baseline, during 12 weeks of treatment

    Registry description

    Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.

Secondary outcomes(20)
  1. Change From Baseline in Mean Number of Nocturnal Voids at Week 1

    Time frame · Baseline, Week 1

    Registry description

    Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2. MMRM=Mixed Model for Repeated Measurements. For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).

  2. Change From Baseline in Mean Number of Nocturnal Voids at Week 4

    Time frame · Baseline, Week 4

    Registry description

    Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

  3. Change From Baseline in Mean Number of Nocturnal Voids at Week 8

    Time frame · Baseline, Week 8

    Registry description

    Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

  4. Change From Baseline in Mean Number of Nocturnal Voids at Week 12

    Time frame · Baseline, Week 12

    Registry description

    Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

  5. Responder Rate in Nocturnal Voids at Week 1

    Time frame · Week 1

    Registry description

    Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

  6. Responder Rate in Nocturnal Voids at Week 4

    Time frame · Week 4

    Registry description

    Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

  7. Responder Rate in Nocturnal Voids at Week 8

    Time frame · Week 8

    Registry description

    Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

  8. Responder Rate in Nocturnal Voids at Week 12

    Time frame · Week 12

    Registry description

    Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

  9. Responder Rate in Nocturnal Voids During 12 Weeks of Treatment

    Time frame · During 12 weeks of treatment

    Registry description

    Defined as 50% reduction in nocturnal voids from baseline. Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

  10. Change From Baseline in Mean NI Diary Total Score at Week 1

    Time frame · Baseline, Week 1

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

  11. Change From Baseline in Mean NI Diary Total Score at Week 4

    Time frame · Baseline, Week 4

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

  12. Change From Baseline in Mean NI Diary Total Score at Week 8

    Time frame · Baseline, Week 8

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

  13. Change From Baseline in Mean NI Diary Total Score at Week 12

    Time frame · Baseline, Week 12

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

  14. Change From Baseline in Aggregated Mean NI Diary Total Score During 12 Weeks of Treatment

    Time frame · Baseline, during 12 weeks of treatment

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items. Responses are scored from 0 to 4 (lowest to highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the mean over the three consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean NI Diary Total Score equal to 40 is presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint.

  15. Percentage of Nights With at Most One Nocturnal Void During 12 Weeks of Treatment

    Time frame · During 12 weeks of treatment

    Registry description

    The percentages of nights during the treatment period with at most one nocturnal void are presented in this endpoint. Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.

  16. Percentage of Nights With No Nocturnal Voids During 12 Weeks of Treatment

    Time frame · During 12 weeks of treatment

    Registry description

    The percentages of nights during the treatment period with complete response, i.e. no nocturnal voids are presented in this endpoint. Level estimated for baseline value of mean number of nocturnal voids equal to 2 is presented in this endpoint.

  17. Change From Baseline in Mean NI Diary Overall Impact Score at Week 1

    Time frame · Baseline, Week 1

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

  18. Change From Baseline in Mean NI Diary Overall Impact Score at Week 4

    Time frame · Baseline, Week 4

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

  19. Change From Baseline in Mean NI Diary Overall Impact Score at Week 8

    Time frame · Baseline, Week 8

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

  20. Change From Baseline in Mean NI Diary Overall Impact Score at Week 12

    Time frame · Baseline, Week 12

    Registry description

    The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall QoL impact question (Q12). For the overall impact question (Q12), response options range from 0 (not at all) to 4 (a great deal). The NI Diary Overall Impact Scores are standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Overall Impact Score are estimated using a baseline value of 40.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· Baseline, during 12 weeks of treatment

Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment

GroupValue (nocturnal voids)
FE 201836 500 ug (Randomized Treatment Period)-1.06
FE 201836 350 ug (Randomized Treatment Period)-0.99
FE 201836 250 ug (Randomized Treatment Period)-0.89
FE 201836 150 ug (Randomized Treatment Period)-0.80
FE 201836 100 ug (Randomized Treatment Period)-0.77
FE 201836 50 ug (Randomized Treatment Period)-0.76
Placebo (Randomized Treatment Period)-0.76
Secondary and other outcome results(7)
Secondary outcomeMean· Baseline, Week 1

Change From Baseline in Mean Number of Nocturnal Voids at Week 1

GroupValue (nocturnal voids)
FE 201836 500 ug (Randomized Treatment Period)-0.714
FE 201836 350 ug (Randomized Treatment Period)-1.162
FE 201836 250 ug (Randomized Treatment Period)-0.722
FE 201836 150 ug (Randomized Treatment Period)-0.520
FE 201836 100 ug (Randomized Treatment Period)-0.722
FE 201836 50 ug (Randomized Treatment Period)-0.325
Placebo (Randomized Treatment Period)-0.575
Secondary outcomeMean· Baseline, Week 4

Change From Baseline in Mean Number of Nocturnal Voids at Week 4

GroupValue (nocturnal voids)
FE 201836 500 ug (Randomized Treatment Period)-1.078
FE 201836 350 ug (Randomized Treatment Period)-1.330
FE 201836 250 ug (Randomized Treatment Period)-0.784
FE 201836 150 ug (Randomized Treatment Period)-0.471
FE 201836 100 ug (Randomized Treatment Period)-0.952
FE 201836 50 ug (Randomized Treatment Period)-0.518
Placebo (Randomized Treatment Period)-0.912
Secondary outcomeMean· Baseline, Week 8

Change From Baseline in Mean Number of Nocturnal Voids at Week 8

GroupValue (nocturnal voids)
FE 201836 500 ug (Randomized Treatment Period)-1.085
FE 201836 350 ug (Randomized Treatment Period)-1.177
FE 201836 250 ug (Randomized Treatment Period)-0.965
FE 201836 150 ug (Randomized Treatment Period)-0.490
FE 201836 100 ug (Randomized Treatment Period)-1.077
FE 201836 50 ug (Randomized Treatment Period)-0.786
Placebo (Randomized Treatment Period)-0.953
Secondary outcomeMean· Baseline, Week 12

Change From Baseline in Mean Number of Nocturnal Voids at Week 12

GroupValue (nocturnal voids)
FE 201836 500 ug (Randomized Treatment Period)-1.256
FE 201836 350 ug (Randomized Treatment Period)-1.120
FE 201836 250 ug (Randomized Treatment Period)-0.850
FE 201836 150 ug (Randomized Treatment Period)-0.674
FE 201836 100 ug (Randomized Treatment Period)-1.053
FE 201836 50 ug (Randomized Treatment Period)-0.921
Placebo (Randomized Treatment Period)-0.957
Secondary outcomeMean· Week 1

Responder Rate in Nocturnal Voids at Week 1

GroupValue (odd of response)
FE 201836 500 ug (Randomized Treatment Period)0.844
FE 201836 350 ug (Randomized Treatment Period)1.202
FE 201836 250 ug (Randomized Treatment Period)0.682
FE 201836 150 ug (Randomized Treatment Period)0.818
FE 201836 100 ug (Randomized Treatment Period)0.810
FE 201836 50 ug (Randomized Treatment Period)0.513
Placebo (Randomized Treatment Period)0.480
Secondary outcomeMean· Week 4

Responder Rate in Nocturnal Voids at Week 4

GroupValue (odd of response)
FE 201836 500 ug (Randomized Treatment Period)1.199
FE 201836 350 ug (Randomized Treatment Period)5.851
FE 201836 250 ug (Randomized Treatment Period)0.634
FE 201836 150 ug (Randomized Treatment Period)0.534
FE 201836 100 ug (Randomized Treatment Period)1.760
FE 201836 50 ug (Randomized Treatment Period)0.683
Placebo (Randomized Treatment Period)1.235
Secondary outcomeMean· Week 8

Responder Rate in Nocturnal Voids at Week 8

GroupValue (odd of response)
FE 201836 500 ug (Randomized Treatment Period)1.395
FE 201836 350 ug (Randomized Treatment Period)3.398
FE 201836 250 ug (Randomized Treatment Period)1.928
FE 201836 150 ug (Randomized Treatment Period)0.877
FE 201836 100 ug (Randomized Treatment Period)1.039
FE 201836 50 ug (Randomized Treatment Period)1.489
Placebo (Randomized Treatment Period)1.503

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
FE 201836 500 µg (Enrichment Period)FE 201836 500 µg oral solution and placebo ODT, administered once daily0 / 5312 / 5310 / 531
FE 201836 500 µg (Randomized Treatment Period)FE 201836 500 µg oral solution and placebo ODT, administered once daily0 / 601 / 6016 / 60
FE 201836 350 µg (Randomized Treatment Period)FE 201836 350 µg oral solution and placebo ODT, administered once daily0 / 272 / 273 / 27
FE 201836 250 µg (Randomized Treatment Period)FE 201836 250 µg oral solution and placebo ODT, administered once daily0 / 241 / 243 / 24
FE 201836 150 µg (Randomized Treatment Period)FE 201836 150 µg oral solution and placebo ODT, administered once daily0 / 140 / 148 / 14
FE 201836 100 µg (Randomized Treatment Period)FE 201836 100 µg oral solution and placebo ODT, administered once daily0 / 131 / 135 / 13
FE 201836 50 µg (Randomized Treatment Period)FE 201836 50 µg oral solution and placebo ODT, administered once daily0 / 340 / 347 / 34
Placebo (Randomized Treatment Period)Placebo oral solution and placebo ODT, administered once daily0 / 872 / 8716 / 87
Desmopressin 25 µg (Randomized Treatment Period)Desmopressin 25 µg ODT and placebo oral solution, administered once daily (female subjects)0 / 260 / 268 / 26
Desmopressin 50 µg (Randomized Treatment Period)Desmopressin 50 µg ODT and placebo oral solution, administered once daily (male subjects)0 / 170 / 179 / 17

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Adults ≥18 years of age (at the time of written consent) * Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1 * ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior to Visit 2 * The largest single voided volume must be ≥200 mL (at least 1 void ≥200 mL) as documented in the 3-day e-Diary prior to Visit 2 * Nocturnal polyuria, defined as Nocturnal Polyuria index \>33%, a ratio of Nocturnal Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in the 3-day e-Diary prior to Visit 2 * ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3-day e-Diary prior to Visit 3 Exclusion Criteria: * Current diagnosis of Obstructive Sleep Apnoea (OSA) * Restless Legs Syndrome (RLS) * Bladder Outlet Obstruction (BOO) or urine flow \<5 mL/s, as confirmed by uroflowmetry upon suspicion during screening prior to Visit 2 * Urinary incontinence defined as an average of \>1 episode/day in the 3-day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary) * Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy or female incontinence procedures * Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms * A history of cancer with the last date of disease activity/presence of malignancy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcinoma of the skin * History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida) * Habitual (fluid intake \>3L per day) or psychogenic polydipsia * Uncontrolled hypertension, as judged by the investigator * Uncontrolled diabetes mellitus, as judged by the investigator * Central or nephrogenic diabetes insipidus * Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion * History of gastric retention * Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA) class II, III, IV) * Hyponatraemia: * Serum sodium level \<135 mmol/L at Visit 1(re-tested, with results available within 7 days) * Serum sodium level \<130 mmol/L at Visit 3 (re-tested, with results available within 7 days) * Use of any prohibited therapy listed below: * Current or former (within 3 months prior to screening) treatment with any other investigational medicinal product (IMP) * Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable electrostimulation or behavioural bladder training program started at least 3 months before screening are acceptable) * Thiazide diuretics * Antiarrhythmic agents * V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin) * Loperamide * Botulinum toxin (cosmetic non-urological use is acceptable) * Valproate

PepBank is a research reference. Talk to a doctor before you use any peptide.